CVRx, Inc.

NASDAQ:CVRX

Medical - Devices

Healthcare
$2.63 +2.28%

+$0.11 today

Market cap
$69.79M
Beta
0.77
P/E (TTM)
-2.5
EPS (TTM)
-$2.00
52W Low $4.37High $11.30

Volume 0.37M

Average 0.30M

CVRX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

CVRx, Inc.NASDAQ: CVRX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.92M rose 18.8% year over year, ahead of the +11.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +41.7% a year.

Context

  • Stock-based compensation amounted to 19.5% of revenue in FY2025, down 17.6 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +18.8% holds above the trailing-twelve-month pace of +11.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.92M+4.4% QoQ
Last fiscal yearDec 2025
$11.05M-42.0% YoY
LTMMar 2026
$11.51M+11.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.8%——
1 year-42.0%——
3-year CAGR+41.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.05M USD
Year-over-year change
-42.0%
4-year CAGR
+55.1%

Stock-Based Compensation vs competitors

How CVRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.1% is the 4th highest of 10, against a peer median of -14.0%.
  • Stock-based compensation amounts to 19.5% of revenue for CVRX, versus a peer median of 14.7%.
CVRX Competitors
Stock-Based Compensation for CVRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CERSCerus CorporationLTM Mar 2026$21.14M USD-10.6%-2.2%9.5%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M USD-30.6%+0.2%14.7%
CVRXCVRx, Inc.LTM Mar 2026$11.51M USD+11.1%+41.7%19.5%
SENSSenseonics Holdings, Inc.LTM Mar 2026$10.59M USD+14.3%+5.6%26.0%
MASS908 Devices Inc.LTM Mar 2026$9.88M USD-14.0%+11.0%17.1%
QTRXQuanterix CorporationLTM Mar 2026$9.79M USD+79.2%+10.3%6.8%
VMDViemed Healthcare, Inc.LTM Mar 2026$9.27M USD+29.4%+20.6%3.2%
NNOXNano-X Imaging Ltd.LTM Dec 2025$4.19M USD-42.3%-39.2%32.2%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$2.38M USD-344.3%—5.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
Peer median (excluding CVRX) —-14.0%+5.6%14.7%

Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.08M)(41.43M)(41.2M)(59.97M)(53.31M)
Depreciation & Amortization168K412K522K619K756K
Deferred Income Tax14.62M0000
Stock-Based Compensation1.91M3.89M6.3M19.05M11.05M
Change in Working Capital(1.58M)(5.57M)(4.81M)949K1M
Accounts Receivables(1.28M)(2.94M)(2.05M)(1.72M)(1.4M)
Inventory(537K)(3.08M)(4.03M)(1.12M)(98K)
Accounts Payables27K1.21M165K698K1.25M
Other Working Capital207K(761K)1.1M3.09M1.25M
Other Non-Cash Items229K25K158K203K327K
Operating Cash Flow(27.73M)(42.68M)(39.02M)(39.14M)(40.17M)
Capital Expenditures(1.18M)(685K)(591K)(1.36M)(580K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(1.18M)(685K)(591K)(1.36M)(580K)
Debt Repayment(21.3M)7.5M22.5M20M0
Common Stock Issued133.16M771K1.66M32.52M10.52M
Common Stock Repurchased(1K)0000
Dividends Paid00000
Other Financing Activities23K(7K)1.48M3.35M0
Financing Cash Flow111.88M7.49M23.98M55.87M10.52M
Effect of Forex Changes(8K)(9K)3K(1K)5K
Net Change in Cash82.96M(35.88M)(15.63M)15.36M(30.23M)
Free Cash Flow(28.92M)(43.36M)(39.61M)(40.51M)(40.75M)

CVRx, Inc.

NASDAQ:CVRX

Intrinsic Alpha fair value

Locked

Current Price

$2.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.